Pharmaceutical company Nutriband Inc (OTCQB:NTRB) revealed on Wednesday the completion of the acquisition of 4P Therapeutics Inc for a purchase price of 250,000 shares of Nutriband's common stock and USD400,000 cash.

Based in Atlanta, 4P Therapeutics is focused on the research and development of transdermal and novel drug delivery technologies and therapeutics, added Gareth Sheridan, CEO of Nutriband.

Upon closing of the acquisition, Nutriband Inc acquires 4P's transdermal prescription pipeline in development, which consists of products to treat opioid abuse /misuse, diabetes, nausea, Infertility, Blood Pressure, Parkinson's disease, and pain relief, which are in various stages of development."

Through this acquisition of 4P, Nutriband now has a pipeline of potential transdermal products. All Nutriband products are based around the science of transdermal /topical technologies.